Outset Medical, Inc. (OM) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call shows strong financial performance with reduced losses and improved cash position. Conservative guidance is balanced by optimism in recurring revenue and pipeline strength. The Q&A section highlights strategic improvements in sales productivity and market expansion, particularly in enterprise and home hemodialysis channels. Concerns about cash burn in 2026 are noted but don't overshadow the overall positive outlook. Given the strategic initiatives and strong recurring revenue, the stock is likely to experience a positive movement in the short term.
Key Financial Performance
Revenue Revenue in the second quarter of $31.4 million grew 15% over last year, driven by strong Tablo console sales and consistent utilization.
Recurring Revenue Recurring revenue of $22.5 million in the quarter increased 11% over the second quarter of last year, including a 17% increase in consumable revenue.
Non-GAAP Gross Margin Non-GAAP gross margin reached 38.4%, expanding more than 1 percentage point from last year, despite a 100 basis point headwind from under-absorption of manufacturing overhead.
Product Revenue Product revenue of $23.1 million grew 20% from $19.2 million in the prior year, driven by console revenue of $8.9 million and consumable revenue of $14.2 million.
Service and Other Revenue Service and other revenue of $8.3 million grew 2% from $8.2 million in the prior year period.
Product Gross Margin Product gross margin increased nearly 400 basis points year-over-year to 48.9%.
Service and Other Gross Margin Service and other gross margin was 6.9% compared to 13.6% in the second quarter of 2024, due to short-term investments in parts supply.
Non-GAAP Operating Expenses Non-GAAP operating expenses declined 19% to $25.4 million compared to the second quarter of 2024.
Non-GAAP Operating Loss Non-GAAP operating loss was $13.4 million, 36% below the operating loss of $21 million in the prior year period.
Net Loss Net loss of $18.5 million was 46% lower than the second quarter of 2024.
Cash Balances Ended the quarter with $187.4 million in cash, cash equivalents, short-term investments, and restricted cash.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Tablo console sales: Revenue in the second quarter of $31.4 million grew 15% over last year, driven by strong Tablo console sales and consistent utilization. Console sales increased sequentially and year-over-year.
Tablo consumables: Recurring revenue of $22.5 million in the quarter, 11% over the second quarter of last year, included a 17% increase in consumable revenue.
Home dialysis market: Finalized an agreement with the third largest midsized dialysis organization, providing access to approximately 15,000 dialysis patients across 30 states. Growing interest in Tablo from patients and providers. Agreements with all 5 of the largest midsized dialysis organizations in the U.S.
Acute care market: Tablo is now in use at more than 900 acute and subacute sites in the U.S. Closed a new enterprise agreement with one of the largest national health systems, providing access to over 100 facilities with potential for hundreds of Tablo console placements.
Gross margin expansion: Non-GAAP gross margin reached 38.4%, expanding more than 1 percentage point from last year. Product gross margin increased nearly 400 basis points year-over-year to 48.9%.
Cost reductions: Actions taken to remove approximately $80 million of annualized spend delivered leverage in the quarter, with a record low non-GAAP operating loss.
Cash management: Used approximately 60% less cash than in the prior year period, on track to use less than $50 million in 2025.
Sales organization transformation: Restructured, retrained, and enhanced the commercial organization, including retooling the capital sales team and implementing a new capital sales process.
Insourcing strategy: Hospitals adopting Tablo for insourcing dialysis services have reported reduced hospital-acquired infections, improved patient care, and better nurse retention.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Federal Funding Cuts: Potential impact from proposed federal funding cuts in healthcare, which could affect customer capital expenditures and demand for Tablo systems.
Manufacturing Overhead Absorption: Lower absorption of manufacturing overhead has been a headwind, impacting gross margins and requiring optimization of inventory levels and production.
Service Gross Margin Decline: Service and other gross margin declined due to short-term investments in parts supply, which could affect profitability.
Cash Use Increase in 2026: Anticipated increase in cash use in 2026 due to ramping up inventory purchasing and production, which could strain financial resources.
Macro Environment Monitoring: Uncertainty in the macroeconomic environment could pose risks to revenue growth and operational execution.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Guidance for 2025: The company raised its revenue guidance for 2025 from $115 million to $125 million to a range of $122 million to $126 million.
Gross Margin Expectations: Gross margin for the full year is expected to be in the high 30% range. Excluding the impact of under-absorption, gross margin is anticipated to exit the year above 40% in the fourth quarter of 2025. The path to 50% gross margin will be driven by higher-margin recurring revenue, service leverage, and a console cost-down program.
Operating Expenses: Operating expenses in 2025 are anticipated to be in the low $90 million range.
Cash Usage: The company expects to use under $50 million in cash in 2025, which is less than half of the cash used in 2024.
Market Demand and Pipeline: The company remains confident in its pipeline and strong market demand for the rest of the year. Customers prioritize capital expenditures for 2025, and the financial and clinical case for insourcing with Tablo remains compelling.
Production and Inventory: The company plans to increase inventory purchasing and ramp production in 2026, with the first quarter of any year expected to be the highest cash-consuming quarter due to incentive compensation payouts.
Strategic Focus Areas: The company is focused on three priorities for 2025: growing console revenue, expanding gross margin, and driving profitability.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Leslie, on your guidance, it seems like the midpoint of the guide makes the second half roughly equivalent to the first half sales level. Is this correct, and why are you being conservative?
A:Leslie confirmed the midpoint of the guide aligns with the second half being roughly equivalent to the first half sales level. She explained the company remains conservative in guidance for 2025 as it focuses on execution. She highlighted strong console and recurring revenue performance in the first half, a growing demand pipeline, and high console utilization as reasons for optimism. However, the company remains committed to conservative guidance to ensure consistent execution.
Q:Can you provide additional color on the commercial strategy transition and the productivity of the sales force?
A:Leslie stated that the commercial organization has undergone significant improvements, including new tools, processes, and team changes. These changes have led to improved forecast accuracy, visibility, and deal progression. The sales force is now more productive and better equipped to handle enterprise-level sales, contributing to the company's positive outlook for the rest of 2025 and beyond.
Q:Can you elaborate on the deal strength in the quarter and the sustainability of the pipeline?
A:Leslie noted strong ASPs due to uptake of newer products like TabloCart and Tablo PRO+ software, as well as disciplined pricing. She emphasized the durability of the pipeline, citing strong console placements and a large enterprise agreement that could drive growth for many quarters. The pipeline is diversified and includes deals at later stages, indicating sustainability.
Q:What will be the focus of the newly hired Chief Nursing Officer?
A:The Chief Nursing Officer will focus on working with the sales organization to help hospitals transition from outsourcing to insourcing dialysis. She will share her experience to assist Chief Nursing Officers at hospitals in understanding the benefits and steps of this transition, aiming to lower costs, reduce complexity, and improve clinical outcomes.
Q:Can you discuss the penetration and opportunity in the enterprise channel or IDN?
A:Leslie described the enterprise channel as being in the early stages, with low double-digit market penetration. She highlighted the interconnectivity between health systems and the benefits of executive leadership migration, which has helped expand the company's footprint. The enterprise channel presents significant growth opportunities for the future.
Q:What are the tailwinds for home hemodialysis in the second half of 2025 and into 2026?
A:Leslie highlighted progress in the home market, with partnerships with all major midsized dialysis organizations and entry into skilled nursing facilities. Retention rates remain high, and the company is focused on deepening utilization in existing locations. Home hemodialysis contributes 15-20% of revenue, and the company expects this mix to remain stable.
Q:How should investors think about the growth trajectory for the home unit versus the acute channel?
A:Leslie stated that the acute and subacute channels will continue to account for 80-85% of revenue, with home contributing the remainder. She does not expect changes in this mix in the near term.
Q:Can you provide more details on the internal work to transform the commercial organization?
A:Leslie explained that the commercial organization has been restructured to focus on enterprise-level sales. This includes hiring experienced capital sales professionals, introducing new data-driven sales tools, and implementing a rigorous sales process. These changes have improved efficiency, forecasting, and deal management.
Q:What is the outlook for cash burn into 2026?
A:Renee stated that the company aims to use less than $50 million of cash in 2025. While cash burn may slightly increase in 2026 due to production ramp-up and one-off items, the company has not provided specific guidance for 2026.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance for cash burn in 2026, stating only that it might slightly increase due to production ramp-up and one-off items. This response lacked detailed projections or clarity on the expected financial trajectory.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ASP strength
Accounting Officer
Allen Wise
BTIG LLC
CFO Principal
CNO hospital
Chairman Gaeta
Cowen Research
Division BTIG
Division Conference
Division Jennings
ET day
Frederick Allen
Gaeta CFO
Gaeta Chief
Incorporated Research
Research Division
United States
access
agreement dialysis
capital sale
care
customer
enterprise
home end
nurse leader
production
sale level
sale process
sale utilization
spend
system country
tariff exemption
OM Transcript
Outset Medical, Inc. (OM) Q1 2026 Earnings Call Transcript
Unknown5-9
The earnings call presents mixed signals. Financial performance shows a revenue decline, but improved margins and reduced net loss. The next-gen Tablo launch and increased service revenue provide optimism, but cash usage and competitive pressures are concerns. The Q&A reveals confidence in future guidance, yet lacks specifics on capital order delays. Thus, the sentiment is neutral, as positives and negatives balance out.
Outset Medical, Inc. (OM) Q4 2025 Earnings Call Transcript
Unknown2-11
While the company has shown improvements in operating expenses and net loss, revenue guidance has been lowered. The Q&A revealed positive sentiment towards the next-gen Tablo's potential impact but lacked specifics on ASP lift and gross margin timelines, which may cause uncertainty. The mixed signals from strong financial metrics but weak guidance, coupled with optimistic future prospects, suggest a neutral short-term stock price movement.
Outset Medical, Inc. (OM) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Outset Medical, Inc. (OM) Q3 2025 Earnings Call Transcript
Unknown11-10
The earnings call presents a mixed picture. Financial performance shows improvement with increased gross margins and reduced losses, but challenges remain with sales leadership changes and guidance reduction. The Q&A reveals uncertainties in deal timing and sales leadership, though no order cancellations occurred. Raised revenue guidance for 2025 is positive, yet the lack of 2026 guidance and management's vague responses add uncertainty. Overall, the sentiment is neutral due to balancing positive financial trends with leadership and guidance concerns.
OM Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
